WALDENSTRÖM MACROGLOBULINEMIA (WM)
Clinical trials for WALDENSTRÖM MACROGLOBULINEMIA (WM) explained in plain language.
Never miss a new study
Get alerted when new WALDENSTRÖM MACROGLOBULINEMIA (WM) trials appear
Sign up with your email to follow new studies for WALDENSTRÖM MACROGLOBULINEMIA (WM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise against rare blood cancer
Disease control OngoingThis study tests a drug called acalabrutinib (ACP-196) in 107 people with Waldenström macroglobulinemia, a rare blood cancer. The goal is to see if the drug can shrink tumors and control the disease. Participants take the drug by mouth, and researchers monitor safety and how well…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA (WM)
Phase: PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Apr 26, 2026 20:00 UTC
-
Is 'Watch and Wait' really 'Worry and Wait'? new study investigates
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how the 'watch and wait' approach affects the quality of life of people with slow-growing lymphomas. Researchers want to know if waiting without treatment causes anxiety or worry. About 250 Korean adults with these cancers will fill out questionnaires to measu…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA (WM)
Sponsor: Seoul National University Hospital • Aim: Knowledge-focused
Last updated May 17, 2026 04:34 UTC